NCT00557011: NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD |
|
|
| Completed | 2 | 52 | US | NRP104, lisdexamfetamine dimesylate, Adderall XR, mixed salts of a single-entity amphetamine, Placebo | New River Pharmaceuticals | Attention Deficit Disorder With Hyperactivity | | 12/04 | | |
NCT00247572: Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories |
|
|
| Completed | 2 | 12 | US | NRP104 | New River Pharmaceuticals | Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders | | 11/05 | | |
NCT01399827: Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits |
|
|
| Completed | 2 | 2 | US | ADHD Medication, Methylphenidate extended release (OROS-MPH), Concerta, Vyvanse, Dextroamphetamine, Adderall, Mixed Amphetamine Salts, Amphetamine, Strattera, Atomoxetine, Focalin, Dexmethylphenidate, Omega-3 Fatty Acids, Nordic Natural EPA Xtra | Massachusetts General Hospital | Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR) | 11/17 | 11/17 | | |
NCT00248092: Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse |
|
|
| Completed | 1/2 | 36 | US | NRP104 | New River Pharmaceuticals | Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders | | 05/06 | | |
